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tTo the Editor: Patients with cardiovascular disease (CVD)
should experience particularly substantial benefits from smoking
cessation. A pertinent meta-analysis estimated that the relative
odds of death in quitting compared with continuing smokers
after myocardial infarction were 0.54 (95% confidence interval:
0.46 to 0.62) (1).
However, most published studies have relied only on self-report
to estimate the impact of smoking cessation on the prognosis of
patients with coronary heart disease (1). Relying on self-report
alone leads to a substantial underestimation of the protective effects
of smoking cessation (2). Therefore, we present updated analyses
of the prospective KAROLA (Langzeiterfolge der Kardiologis-
chen Anschlussheilbehandlung [Long-Term Success of Cardio-
logic Rehabilitation Therapy]) cohort study (2). Patients admitted
from January 1999 to May 2000 to 1 of 2 participating rehabili-
tation clinics for in-hospital rehabilitation within 3 months after
acute myocardial infarction or coronary syndrome or coronary
artery intervention were eligible for participation, conditional on
the provision of written informed consent. The study was approved
by the ethics boards of the physicians’ chambers of Hessen and
Baden-Württemberg and of the University of Ulm and the
University of Heidelberg.
Baseline and follow-up procedures featuring self-administered
standardized questionnaires for patients and treating physicians
over 8 years have been described elsewhere (2). Causes of death
ere ascertained through public health authorities. Blood sam-
les for smoking status validation were taken at rehabilitation
ischarge and 1 and 3 years later by the participants’ general
ractitioners. The samples were mailed to the study center and
tored at 80°C until analysis, for which a commercial serum
otinine radioimmunoassay was used (Immundiagnostik AG,
ensheim, Germany).
Smoking behavior was handled in 4 different ways. First,
articipants were classified as nonsmokers (15 ng/ml) or smokers
15 ng/ml) on the basis of cotinine levels at the end of the
npatient rehabilitation program (3). Second, the nonsmokers were
urther differentiated according to self-report (obtained through
uestionnaires at the beginning of inpatient rehabilitation) into
ever smokers, former smokers, and former smokers who had quit
nly after their acute cardiovascular events. Third, analyses were
estricted to participants whose cotinine-based status did not
hange from baseline to years 1 and 3 follow-up (although this
ntroduced a positive bias by including follow-up information as if
vailable at baseline, it represented an informative extreme expo-
ure comparison). Last, all cotinine information was ignored, and
elf-report was relied on solely.
The main analysis was by Cox models predicting secondary
ardiovascular events (physician-reported nonfatal myocardial
nfarction or ischemic stroke or CVD as main cause of death[International Classification of Diseases-9th Revision, codes
390 to 459; International Classification of Diseases-10th Revi-
sion, codes I00 to I99; 1 case of code R57.0]). Adjusted models
controlled for confounders important in our cohort (2).
Of 1,206 subjects initially included, complete data were avail-
able for 1,062 (88.1%). The participants were predominantly men
(84.7%), with a mean age of 59  8.0 years. The median
bservation time was 8.1 years (interquartile range: 6.1 to 8.2
ears), and 154 secondary CVD events occurred. Of these, 51 were
onfatal myocardial infarctions, 41 were nonfatal ischemic strokes,
nd 62 were deaths with CVD as the main cause.
Cotinine measurements revealed nonabstinence at rehabilita-
ion discharge in 123 of 1,009 participants (12.2%) who, according
o self-report, were abstinent at the start of inpatient rehabilitation.
t the same time, 22 of 53 participants (41.5%) who reported
ontinuing to smoke at the beginning of rehabilitation had
ischarge cotinine values less than 15 ng/ml, suggesting that they
ad since quit. For 948 and 833 subjects, serum cotinine concen-
rations were also available for year 1 and 3 follow-up, respectively.
n the basis of these measurements, 159 of 908 participants
17.5%) who were abstinent at baseline started or restarted
moking during follow-up (cotinine at years 1 or 3 15 ng/ml),
hereas 56 of 154 participants (36.4%) who had continued
moking at the end of inpatient rehabilitation quit smoking at least
emporarily during this time (cotinine at years 1 or 3 15 ng/ml).
Compared with continuing smokers, risks were reduced for
all other groups, regardless of how smoking status was assessed
(Table 1). The risk in participants classified as abstinent on the
basis of cotinine measurements was halved. With additional
differentiation on the basis of self-report, the risk was estimated to
be reduced by more than 50% in both never smokers and those
who had quit after their acute CVD events. If misclassification was
further reduced by excluding participants whose smoking status
changed during follow-up, subjects in all 3 nonsmoking categories
showed strongly reduced risk in comparison with continuing
smokers, with reductions of about 70% and 80%. In contrast, when
cotinine was ignored and smoking was assessed on the basis of
self-report alone, only the risk reduction in never smokers came
close to statistical significance.
In this cardiovascular patients cohort, nonsmoking and cessa-
tion strongly predicted event-free survival. A statistically signifi-
cant benefit could be seen only when smoking status was assessed
with cotinine validation. Remarkably, the hazard ratios were at
least as favorable for former smokers who had quit after their acute
events as for never smokers, and smoking cessation appeared to
lead to a reduction or normalization of cardiovascular risk very
rapidly. A recent authoritative pertinent Cochrane review con-
cluded that “it is unlikely that further work exploring the magni-
tude and speed of effect of smoking cessation is needed” (4). The
findings described here urge us to voice dissent with this point of
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of misclassification to better understand the benefits of smoking
cessation, as such knowledge is necessary for fully informing
smoking patients about the impact their own behavioral choices
have on their prognoses.
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Table 1
Cox Regression Resul s: Multivariate Survival An ysis for Fata
With Smoking Status Defined by Different Sources of Informatio
Smoking Status Definition
1. Cotinine at rehabilitation discharge (ng/ml)
15
15
2. Further differentiating abstainers according to self-report
Continuing smoking (15 ng/ml)
Quit after acute event (15 ng/ml)
Formerly smoking (15 ng/ml)
Never smoking (15 ng/ml)
3. Like definition 2, but restricted to subjects whose
smoking status did not change during follow-up‡
Continuing smoking (15 ng/ml)
Quit after acute event (15 ng/ml)
Formerly smoking (15 ng/ml)
Never smoking (15 ng/ml)
4. Self-report at baseline
Continuing smoking
Quit after acute event
Formerly smoking
Never smoking
Analyses were performed using SAS version 9.1 (SAS Institute Inc., Cary, North Carolina). *Adju
lipoprotein cholesterol, and angiotensin-converting enzyme medication at discharge. ‡Changes i
clarification.
CI  confidence interval; HR  hazard ratio.doi:10.1016/j.jacc.2011.01.045lease note: This work was supported in part by grant 01GD9820/0 from the
ederal Ministry of Education and Research, the Pitzer Foundation, and grant
r1704/11-1 from the German Research Foundation’s priority program SPP1226
Nicotine.” The funding agencies had no role in study design, conduct, analysis,
r publication. Dr. Rothenbacher was a full-time employee of Novartis Pharma
G until November 2010.
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ents) HR (95% CI)* HR (95% CI)†
30) 1.00 (reference) 1.00 (reference)
124) 0.57 (0.38–0.86) 0.52 (0.35–0.79)
30) 1.00 (reference) 1.00 (reference)
15) 0.45 (0.24–0.85) 0.38 (0.20–0.73)
71) 0.69 (0.45–1.08) 0.62 (0.40–0.97)
38) 0.47 (0.29–0.78) 0.47 (0.28–0.78)
24) 1.00 (reference) 1.00 (reference)
6) 0.22 (0.09–0.53) 0.17 (0.06–0.44)
58) 0.46 (0.28–0.75) 0.42 (0.25–0.70)
34) 0.33 (0.19–0.57) 0.32 (0.18–0.55)
10) 1.00 (reference) 1.00 (reference)
27) 0.68 (0.33–1.41) 0.75 (0.35–1.60)
78) 0.63 (0.32–1.24) 0.68 (0.33–1.37)
39) 0.41 (0.20–0.84) 0.48 (0.23–1.02)
r sex and age. †Adjusted additionally for prevalent diabetes, triglycerides, total and low-density
ing status as assessed by cotinine measurements at years 1 and 3 follow-up; also see text forSeconl or N
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